Multiple clinical study results of ABRAXANE to be presented by Abraxis BioScience
 

Abraxis BioScience, Inc., a fully integrated biotechnology company, today announced that multiple clinical studies of the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) will be presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS), being held in San Antonio, Texas from December 9 to December 13.

More...